U.S. FDA authorises new saliva sample collection for Covid-19
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
U.S. FDA to decide whether to authorize a booster dose in the coming days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Subscribe To Our Newsletter & Stay Updated